Navigation Links
Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
Date:5/13/2009

DURHAM, N.C., May 13 /PRNewswire/ -- Addrenex Pharmaceuticals today expanded its pipeline of products aimed at adrenergic regulation with the signing of an agreement to license a new drug for the treatment of narcolepsy, a chronic and debilitating sleep disorder, as well as other neurologic and psychiatric conditions.

The agreement to license ADX-N05 gives Addrenex the worldwide rights (excluding East Asia) to develop, manufacture and commercialize the compound from SK Life Science Business Division, the drug-discovery and development division of SK Holdings Co. Ltd., one of the largest multinational companies based in South Korea.

"The partnership with SK Holdings embodies our commitment to seeking global alliances that further our goal of developing drugs for adrenergic regulation," said Steve Butts, Vice President of Commercial Operations for Addrenex Pharmaceuticals.

"We are pleased and excited to partner with an innovative, dynamic company such as SK Holdings, and we expect this to be the first of many global development partnerships for Addrenex," he added.

The licensing deal with SK Holdings provides Addrenex with its fourth drug candidate to enter clinical trials in three years. Each of Addrenex's drugs in development focuses on the treatment of medical conditions arising from an overactive or improperly regulated adrenergic system, a group of hormones and brain chemical messengers known as neurotransmitters. These hormones and neurotransmitters regulate diverse physiologic functions such as stress, pain, sleep and blood pressure.

Addrenex's lead products are Clonicel(R) for the treatment of attention-deficit hyperactivity disorder (ADHD) and Sympres(R) for the treatment of hypertension. The company also plans to develop drugs to treat menopausal flushing and potentially pain, insomnia and migraines, all of which are impacted by the adrenergic system.

'/>"/>

SOURCE Addrenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
2. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
3. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
4. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
5. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
6. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting
7. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
8. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
9. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
10. Transcept Pharmaceuticals to Report First Quarter 2009 Results
11. Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... THE WOODLANDS, Texas , Nov. 21, 2014 /PRNewswire/ ... announced the pricing of its previously announced underwritten public ... pursuant to an effective shelf registration statement. The offering ... a public offering price of $1.005 per share.  Lexicon ... purchase up to 7,462,687 additional shares of common stock.  ...
(Date:11/18/2014)... LOS ANGELES , Nov. 18, 2014 /PRNewswire/ ... technology development, patient engagement and study recruitment – ... platform, called Sangre, to help Pfizer Inc. find ... Pain (CIP) and their family members to participate ... help potentially identify DNA mutations and hopefully aid ...
(Date:11/18/2014)... 18, 2014  TransCelerate BioPharma Inc. ("TransCelerate") ... manuscript on Risk-Based Monitoring (RBM), " Evaluating ... Measure in Clinical Trials ," in the ... Regulatory Science  (TIRS) journal. Developed by TransCelerate,s ... the manuscript examines the value of Source ...
Breaking Medicine Technology:Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3Sanguine's Mobile Application to Assist Recruitment for Pfizer Inc. Chronic Pain Research 2TransCelerate BioPharma Inc. Publishes Recommendation on Use of Source Data Verification in Risk-Based Monitoring, Releases Third Update on Initiative Progress 2TransCelerate BioPharma Inc. Publishes Recommendation on Use of Source Data Verification in Risk-Based Monitoring, Releases Third Update on Initiative Progress 3
... to 3D Composer Series -- MATUYAMA-CITY, Japan, Sept. 24 ... ... ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
... Terminate Existing Co-Promotion Agreement and Acquire U.S. Rights to... -- ARDEE, Ireland, Sept. 24 ... ... --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Medicine Technology:3D FS-Composer Added to 3D Composer Series 23D FS-Composer Added to 3D Composer Series 33D FS-Composer Added to 3D Composer Series 43D FS-Composer Added to 3D Composer Series 53D FS-Composer Added to 3D Composer Series 6Warner Chilcott Agrees to Terminate Existing Co-Promotion Agreement and Acquire U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 2Warner Chilcott Agrees to Terminate Existing Co-Promotion Agreement and Acquire U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 3Warner Chilcott Agrees to Terminate Existing Co-Promotion Agreement and Acquire U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 4Warner Chilcott Agrees to Terminate Existing Co-Promotion Agreement and Acquire U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 5Warner Chilcott Agrees to Terminate Existing Co-Promotion Agreement and Acquire U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 6Warner Chilcott Agrees to Terminate Existing Co-Promotion Agreement and Acquire U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 7Warner Chilcott Agrees to Terminate Existing Co-Promotion Agreement and Acquire U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 8Warner Chilcott Agrees to Terminate Existing Co-Promotion Agreement and Acquire U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 9
(Date:11/21/2014)... November 21, 2014 For many busy people, ... office visits and months of recovery from dental surgery that ... even at the cost of their youthful appearance. , But ... Art Institute in Oxnard and Woodland Hills, Calif., can provide ... visit, even in instances where the patient’s bone has deteriorated. ...
(Date:11/21/2014)... MO (PRWEB) November 21, 2014 ... Melancholy Lift, an industry leader in the ... people have significant feelings of sadness and depression ... from traditional pharmaceutical choices. Often, prescription drugs can ... depression. Prescription drugs are expensive and require regular ...
(Date:11/21/2014)... Florida (PRWEB) November 21, 2014 Nature’s Sleep is ... Sleep contest . The contest calls for the creation of any ... a photo — that encompasses sleep, a bed or a mattress. ... year,” said Alan Hirschhorn, Vice President of Marketing for Nature’s Sleep, ... an array of more than 10,000 creative entries from some very ...
(Date:11/21/2014)... people with cochlear implants experience pain, discomfort and problems ... MRI scan, a new study finds. According to ... worldwide have cochlear implants, devices which provide a sense ... severe hearing loss. There have been prior reports of ... One expert said the problem is well-known among ...
(Date:11/18/2014)... 18, 2014 SnapMade , a ... for shoppers in this holiday season, celebrates the oncoming ... Commenting on the launch, Carl Beleek, Group Managing Director ... their customers both old and new in supporting them ... this opportunity to launch new ornaments to better serve ...
Breaking Medicine News(10 mins):Health News:Anacapa Dental Art Institute Prosthodontists Develop New Technique to Offer Younger Appearance in Just One Visit 2Health News:Anacapa Dental Art Institute Prosthodontists Develop New Technique to Offer Younger Appearance in Just One Visit 3Health News:Anacapa Dental Art Institute Prosthodontists Develop New Technique to Offer Younger Appearance in Just One Visit 4Health News:Anacapa Dental Art Institute Prosthodontists Develop New Technique to Offer Younger Appearance in Just One Visit 5Health News:Depression Relief Product Receives Top 5-Star Rating from TopConsumerReviews.com 2Health News:Nature’s Sleep Kicks Off their 2nd Art Of Sleep Contest 2Health News:MRI Can Be Painful, Disruptive for People With Cochlear Implants 2Health News:SnapMade Celebrates Christmas With Exciting New Launches 2
... announced that it,has succeeded in obtaining registration for ... systems with the British Standards Institution,(BSI). KFH,s ... are delighted,to have achieved registration to these top ... a major milestone for a young company, and,one ...
... in Cambridge, famous as a haunt of students in ... the next generation of antibiotics, according to scientists speaking ... General Microbiologys 161st Meeting at the University of Edinburgh, ... antibiotics now over-prescribed for treatments of bacterial infections, and ...
... Calif. - A blood cell known as a troublemaker for ... cell, can also calm down the flare-ups, researchers from Stanford ... be published Sept. 2 in the online version of Nature ... damage over time from sun exposure or from poison oak. ...
... drug delivery system designed for brain tumour therapy has ... culture model devised by scientists at The University of ... Pharmacy, Biomedical Sciences and Human Development, will be featured ... Medicine. , Therapy for brain cancers is particularly difficult ...
... back to ... HACKETTSTOWN, N.J., Sept. 1 Prolific NASCAR driver,Ricky Rudd celebrates ... - a milestone achieved by just one other driver in ... will be outfitted,with a new brand - Generation Max(R) - ...
... Ill. The first investigation of developmental sleep duration ... and who get little sleep are more likely to ... to a study published in the September 1 issue ... Jacques Montplaisir, MD, of the Sleep Disorders Center at ...
Cached Medicine News:Health News:New viruses to treat bacterial diseases -- 'My enemies' enemy is my friend' 2Health News:Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find 2Health News:Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find 3Health News:Novel 3-D cell culture model shows selective tumour uptake of nanoparticles 2Health News:Video: Nutrition Comes to NASCAR 2Health News:Video: Nutrition Comes to NASCAR 3Health News:Lack of sleep among new school-goers leads to behavioral, cognitive problems 2Health News:Lack of sleep among new school-goers leads to behavioral, cognitive problems 3
IDS Rapid One, a microbial identification system....
IDS Rapid NF Plus, a microbial identification system....
Versatrek 240 is versatile as four tests can be performed on one platform such as blood culture, sterile body fluids, mycobacteria and mycobacteria susceptibility testing. This model comes equipped w...
BD Phoenix is an automated microbiology system used for identification and susceptibility testing....
Medicine Products: